Chennai, Tamil Nadu -- (SBWIRE) -- 05/14/2012 -- "Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

31st August 2012, Hyatt Regency, Mumbai, India.

For more info on the event and for event brochure kindly visit –

http://www.virtueinsight.com/pharma/3rd-Annual-Pharmacovigilance-2012/

Key Themes Discussed at this Summit:
- Exploiting the latest technologies, methodologies and Introducing pharmacy automations on work practices of Pharmacovigilance
- Keeping abreast of the changes impacting the drug safety industry to ensure the pharmacovigilance strategies are robust and geared to compliance
- Recent successful strategies and business models to bring out new medicines
- How will PV activities change with Clinical Trial Transformation Initiative?
- Identifying essential antidote requirements and learn to implement best practices in drug safety and surveillance
- Exploiting the pharmacy automations and technologies for enhancement of medication safety
- Stay ahead of computing and electronic communications in pharmacovigilance
- Latest developments in pharmacovigilance, drug safety and risk management to ensure safer drugs to market
- Establishing the importance of pharmacovigilance for the safety of the patient
- Determining the steps and strategies for enhancing quality in healthcare
- Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
- Analyzing the information on current industry projects and trends
- Identifying the latest regulatory framework for pharmacovigilance
- Global marketing strategies in order to engage with regulatory centers of excellence on pharmacovigilance
- Accelerating new medicine introduction in developing world & overcoming challenges
- Explaining how to use the data sources and observational research for effective safety analysis
- Good supply chain management practices for medicine distribution
- Be part of a major networking opportunity

Key Speakers:
- Bhaswat S. Chakraborty, Senior VP & Chair, Research and Development, Cadila
- Arun Bhatt, President, Clininvent Research
- Vinod Mattoo, Medical Director, Metabolic Disease Strategy, Asia-Pacific, Bristol-Myers Squibb (Singapore)
- Dilip Pawar, Director and Head - Clinical Development, Dr Reddys
- Babita Kirodian, Head - Country Pharmacovigilance, Bristol Myers Squibb
- Hari Prasad, CEO, Apollo Hospitals
- Rajani Rokade, Head - Pharmacovigilance, Sanofi Aventis
- Manish R Garg, Country Medical Director India, Bayer
- Siddarth Chachad, Head - Medical Services, Cipla
- Indu Nambiar, Clinical Safety Officer(CSO), Boehringer Ingelheim
- Simrat Sohal, Clinical Research Physician - Patient safety and Critical care, Eli Lilly
- Milind Antani, Head - Pharma LifeSciences group, Nishith Desai Associates

Plus Many More...

Who Should Attend:
VP's, Directors, CRO's, Heads and Managers of:
- Pharmacovigilance Strategy
- Drug Safety/Risk Management
- Information and Clinical Data Management
- Clinical Research
- Research & Development
- Product Safety/Assurance Assessment
- Patient Safety & Outcomes Research & Data Analysis
- Epidemiology project management
- Regulatory Affairs and Compliance
- Sales & Marketing
- Biotech manufacturers

Why Should You Attend:

3rd Annual Pharmacovigilance 2012- "Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management "

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Ordering Delegate Place –
Register Now as delegate, sponsor, exhibitor or order for free visitor pass

Early Bird Discounted Price - Conference Delegate Pass (INR 4,000 + Tax (12.36%) per delegate) - Book and Pay before 31st June 2012 to avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL: + 91 44 64536444. Email – tania@virtueinsight.com

Standard Price after 31st June 2012 - Conference Delegate Pass (INR 6,000 + Tax (12.36%) per delegate) - You can simply email or call and book your conference delegate seats on TEL: + 91 44 64536444. Email – tania@virtueinsight.com

Group Discounts - 2 or 3 Delegates - (INR 5,000 + Tax (12.36%) per delegate)

Group Discounts - 4 and above Delegates - (INR 4,000 + Tax (12.36%) per delegate)

Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to – TEL: + 91 44 64536444. Email – tania@virtueinsight.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Chennai, Tamil Nadu -- (SBWIRE) -- 12/25/2011 -- "Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

February 24th 2012, Hilton London Euston Hotel, London UK

For more info on the event and for event brochure kindly visit: http://www.virtueinsight.com/pharma/Biosimilars-Congregation-2012/

Key Themes Discussed at this Summit:

- Reviewing some of the challenges in clinical study design for biosimilar development arising from endpoint variability, changes in clinical practice, and evolution in understanding of the biology of the disease

- How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars

- How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?

- Identifying issues and solutions surrounding biosimiliars and clinical trials.

- Next generation monoclonal antibody development and clinical challenges with biosimilar drug development

- Overcoming pricing and reimbursement challenges to maximise the ROI

- Determining the right investments & potential returns from Biosimilars

- Commercial challenges and opportunities - strategies to develop Biosimilars

- Biosimilars Vs Bio-betters – positioning for a new market with lucrative prospects

- Learn to implement best practices through recent successful strategies and business models – real time case studies

- Analyze the FDA's current view of biosimilars

- The developing regulatory framework in advanced and developing markets

- EMA Regulatory Opinions on Treatment of mAbs

- Critical issues in demonstrating biosimilarity and maintaining diligent quality control

- Be part of a major networking opportunity

Who Should Attend:

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:
- Analytics
- Business Development
- Business Strategy
- Corporate Development Strategy
- Commercial Affairs
- Intellectual Property
- Marketing & Sales
- Medical Affairs
- NewProduct Development
- Legal Affairs
- CMC
- Preclinical and Clinical Development
- Product Development
- Regulatory Affairs
- Pricing and Reimbursement
- Research and Development
- Biologic Production
- Quality Assurance
- Scientific Affairs
- Strategic Planning

- Strategic Sourcing

Key Speakers Include:
- Claudio Carini, Translational Medicine, Pfizer
- Deven Parmar, Vice President - Global Clinical Research, Wockhardt (India)
- Paul Greenland, Biosimilars and Proprietary Marketing Director – EMEA, Hospira, UK
- Keith Powell, Chairman, Domainex (Former CEO, Polytherics)
- Cecil Nick, Vice President - Biotechnology, Parexel
- Richard Dennett, Director, Voisin Consulting Life Sciences
- Lincoln Tsang, Partner, Arnold & Porter LLP
- Kristie C. Kuhl, Senior Vice President, Makovsky + Company (USA)
- Violeta Stanimirovic, Expert of medicines and medical devices agency, Serbia-Alims & expert of Montenegrian National Drug Agency – CALIMS
- Francis P. Crawley, Executive Director, Good Clinical Practice Alliance – Europe (GCPA)
- Anthony Grosso, Associate Professor in Clinical Pharmacy Practice (Honorary), UCL Hospitals NHS Trust, University of London
- Jan Petracek, MD MSc DIC CEO, Pharminvent
- Anna Harrington Morozova, Scientific & Regulatory Director, REGEM Consulting
- Steinar Madsen, Medical Director, Norwegian Medicines Agency
- Duncan Emerton, Prinicpal Consultant, Datamonitor
plus many more.........

Why Should You Attend:

Biosimilars Congregation 2012 – "Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition.

Expand your knowledge of the latest business models and strategies in the high-level conference.

Ordering Delegate Place –
Register now as delegate, sponsor and exhibitor

Early Bird Discounted Price - Conference Delegate Pass (£ 400 + VAT per delegate) - Book and Pay before 20th December 2011 to avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444.

Email – tania@virtueinsight.com

Standard Price after 20th December 2011 - Conference Delegate Pass (£ 500 + VAT per delegate) - You can simply email or call and book your conference delegate seats on TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444..
Email – tania@virtueinsight.com

Group Discounts - 2 or 3 Delegates - £ 350 + VAT per delegate

Group Discounts - 4 and above Delegates - £ 300 + VAT per delegate

Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to – TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444.

Email - tania@virtueinsight.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm